Your browser doesn't support javascript.
loading
Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.
Reed, Damon R; Mascarenhas, Leo; Manning, Kathleen; Hale, Gregory A; Goldberg, John; Gill, Jonathan; Sandler, Eric; Isakoff, Michael S; Smith, Tiffany; Caracciolo, Jamie; Lush, Richard M; Juan, Tzu-Hua; Lee, Jae K; Neuger, Anthony M; Sullivan, Daniel M.
Afiliación
  • Reed DR; Sarcoma Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Mascarenhas L; Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Manning K; Adolescent and Young Adult Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Hale GA; All Children's Hospital, Johns Hopkins Medicine, St. Petersburg, Florida.
  • Goldberg J; Division of Hematology, Oncology, Blood and Marrow Transplantation, Department of Pediatrics, Children's Hospital of Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Gill J; Sarcoma Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Sandler E; All Children's Hospital, Johns Hopkins Medicine, St. Petersburg, Florida.
  • Isakoff MS; University of Miami, Miami, Florida.
  • Smith T; Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York.
  • Caracciolo J; Nemours Children's Cancer Center, Jacksonville, Florida.
  • Lush RM; Connecticut Children's Medical Center, Hartford, Connecticut.
  • Juan TH; Sarcoma Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Lee JK; Department of Diagnostic Imaging, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Neuger AM; Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Sullivan DM; Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Cancer Med ; 5(2): 294-303, 2016 Feb.
Article en En | MEDLINE | ID: mdl-26714427
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Aromoterapia Asunto principal: Compuestos de Fenilurea / Niacinamida / Inhibidores de Proteínas Quinasas / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies Idioma: En Revista: Cancer Med Año: 2016 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Aromoterapia Asunto principal: Compuestos de Fenilurea / Niacinamida / Inhibidores de Proteínas Quinasas / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies Idioma: En Revista: Cancer Med Año: 2016 Tipo del documento: Article